Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
Biotech Penny Stocks Investing Guide
04:47pm, Monday, 20'th Jun 2022
What to know about trading biotech stocks in 2022 The post Biotech Penny Stocks Investing Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks to Watch as the Market Crashes Again
03:37pm, Thursday, 16'th Jun 2022
Here are three penny stocks to add to your watchlist right now The post Best Penny Stocks to Watch as the Market Crashes Again appeared first on Penny Stocks to Buy, Picks, News and Information | Penn
Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
05:26pm, Wednesday, 15'th Jun 2022 Zacks Investment Research
Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.
3 Stocks Under $1 Insiders Are Buying
12:22pm, Tuesday, 14'th Jun 2022 Benzinga
The Nasdaq Composite dropped by more than 500 points on Monday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or co
Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks
04:48pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.
Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks
02:17pm, Thursday, 09'th Jun 2022
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.
Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2022
02:16pm, Thursday, 09'th Jun 2022 Benzinga
Upgrades
Keefe, Bruyette & Woods upgraded the previous rating for AGNC Investment Corp (NASDAQ:AGNC) from Market Perform to Outperform. In the first quarter, AGNC Investment showed an EPS of $0.72, co
Expert Ratings for Rigel Pharmaceuticals
02:00pm, Thursday, 09'th Jun 2022 Benzinga
Rigel Pharmaceuticals (NASDAQ:RIGL) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
3
0
0
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022
02:03pm, Wednesday, 08'th Jun 2022 Benzinga
Upgrades
For Crescent Point Energy Corp (NYSE:CPG), Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. In the first quarter, Crescent Point Energy showed an EPS of $0.32,
Why Rigel Pharmaceuticals Shares Are Falling Today
10:19am, Wednesday, 08'th Jun 2022
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares are trading lower after the company announced data from the FORWARD Phase 3 clinical trial of Fostamatinib did not demonstrate statistical significanc
Rigel Pharmaceuticals' Fostamatinib Flunks In Late-Stage Rare Blood Disorder Trial
09:47am, Wednesday, 08'th Jun 2022
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) shares are falling on disappointing data from the FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA). wAIHA is
Rigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call Transcript
11:01pm, Tuesday, 03'rd May 2022
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Dolly Vance - EVP, Corporate Affairs and General Counsel Raul Rodriguez - Presid
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Misses Revenue Estimates
09:35pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Rigel (RIGL) delivered earnings and revenue surprises of -33.33% and 9.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Misses Revenue Estimates
06:49pm, Tuesday, 03'rd May 2022
Rigel (RIGL) delivered earnings and revenue surprises of -33.33% and 9.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
